MediWound's Q3: Mixed Financial Results

MediWound Limited, an Israeli pharmaceutical firm, reported a net loss of $2.7 million for Q3, translating to a loss of $0.24 per share. Despite this, their performance was better than predicted, as analysts had forecasted a loss of $0.81 per share. However, revenue fell short of expectations, with $5.4 million reported instead of the anticipated $6.4 million.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.